CITIUS ONCOLOGY, INC. (CTOR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US17331Y1091
CITIUS ONCOLOGY, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -23.52 m USD |
| EBIT | -23.52 m USD |
| Net income | -24.76 m USD |
| Diluted EPS – continuing operations | -0.34 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CITIUS ONCOLOGY, INC.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
More stocks
- Nano One Materials Corp (NANO.TO)
- Wp Energy Public Company Limited (WP.BK)
- Buana Finance Tbk (BBLD.JK)
- Kraft Bank Asa (KRAB.OL)
- Guru Organic Energy Corp (GURU.TO)
- D&C Media Co.Ltd (263720.KQ)
- Unick Corporation (011320.KQ)
- First Breach Inc. Common Stock (FBDT)
- EM-Tech.CO. LTD (091120.KQ)
- FST Corp. Ordinary Shares (KBSX)
- Taewoong Logistics Co.Ltd (124560.KQ)
- Yenher Holdings Bhd (5300.KL)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.